Drug intelligence / Profile preview

PPC 325

Development stage: Preclinical
Lead developer: Phytomyco Research
Modality: Small Molecules

Overview

PPC 325 is a natural product-derived small molecule therapeutic candidate being developed by Phytomyco Research for the treatment of tuberculosis. As an anti-mycobacterial agent, it is designed to target and inhibit the growth of *Mycobacterium tuberculosis*. The drug is currently in the preclinical stage of development, with studies being conducted at the animal level to evaluate its efficacy and safety profile. Phytomyco Research focuses on leveraging bioactive compounds from natural sources, and PPC 325 represents one of their lead assets in the infectious disease space.

Beyond the preview

Go deeper on PPC 325.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PPC 325.

Explore the full profile